Product
Recombinant novel coronavirus vaccine
Aliases
Recombinant novel coronavirus vaccine (CHO cells)
4 clinical trials
1 indication
Indication
COVID-19Clinical trial
Study on the Immunogenicity and Safety of Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) After Inoculation With Two Doses of Inactivated Vaccine (CoronaVac) in People Over 18 Years OldStatus: Completed, Estimated PCD: 2022-06-03
Clinical trial
To Evaluate the Immunogenicity and Safety of Booster Immunization 12 Months After the Completion of Basic Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cell) in People 18 Years Old and AboveStatus: Completed, Estimated PCD: 2022-07-19
Clinical trial
To Evaluate the Immunogenicity and Safety of Booster Immunization 6 Months After the Completion of Basic Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cell) in People 18 Years Old and AboveStatus: Completed, Estimated PCD: 2022-08-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 YearsStatus: Completed, Estimated PCD: 2020-11-30